[Featured Stock] Has the Momentum Faded? 'Exciting Triple Rise' SK Bioscience... Explosive Trading Volume

[Asia Economy Reporter Lee Seon-ae] SK Bioscience's stock price is showing an upward trend, but it is expected to be difficult to achieve a 'ttasang-sang'?hitting the upper price limit for two consecutive days after the opening price is set at twice the IPO price.

According to the Korea Exchange on the 19th, as of 9:19 AM, SK Bioscience's stock price is trading at 181,000 KRW, up 7.10% from the previous day. It rose to 190,000 KRW in early trading. It is currently trading at 180,000 KRW, up 11,000 KRW (6.51%).

At the same time, the trading volume has exceeded 5 million shares. Although the previous day's trading volume was only 870,000 shares, the volume has significantly increased today. This is interpreted as selling pressure intensifying as momentum weakens. The freely tradable shares of SK Bioscience account for 11.6% of the total shares, approximately 8.9 million shares.

On the first day of listing, SK Bioscience's stock price closed at the upper limit, rising 30% (39,000 KRW) from the opening price to 169,000 KRW. The opening price was set at 130,000 KRW, twice the IPO price of 65,000 KRW, and immediately surged to the upper limit, rising more than 160% compared to the IPO price.

The market capitalization reached 12.9285 trillion KRW, ranking 28th on the KOSPI market. Within two minutes of the market opening on the first day, SK Bioscience hit the upper limit, triggering both static and dynamic volatility interruption devices (VI) due to the rapid price surge.

SK Bioscience was established in 2018 by a physical division of SK Chemicals' vaccine business unit. It is contract manufacturing COVID-19 vaccines developed by AstraZeneca and Novavax. At the same time, it is accelerating the development of two COVID-19 vaccine candidates (GBP510 and NBP2001). Additionally, it develops and sells vaccines for influenza, shingles, and chickenpox.

Lee Hye-rin, a pharmaceutical and bio researcher at KTB Investment & Securities, stated, "SK Bioscience has firmly established itself as the leading domestic vaccine maker after COVID-19," and added, "The significantly expanded business opportunities with global vaccine makers will also act as a factor for valuation increase."

This content was produced with the assistance of AI translation services.